Significance of IL-1beta and IL-1 receptor antagonist (IL-1Ra) in bronchoalveolar lavage fluid (BALF) in patients with diffuse panbronchiolitis (DPB).
We evaluated the effect of erythromycin therapy on pulmonary function tests and the airway inflammatory response of patients with DPB. The number of neutrophils in BALF obtained from DPB patients was significantly higher than that of healthy volunteers. Treatment with erythromycin (600 mg/day for 12.9+/-9.5 months (mean +/- s.d.)) significantly reduced the total number of cells and neutrophils in the airway, and significantly improved pulmonary function tests. The levels of IL-1beta and IL-8 were significantly higher in DPB compared with healthy volunteers (P<0.05, P<0.05, respectively). IL-1Ra in patients is considered to have a weak inhibitory activity for IL-1beta, with approximately five-fold concentration of IL-1beta compared with that in healthy volunteers (approx. nine-fold concentration of IL-1beta). Erythromycin therapy significantly reduced these cytokines to levels comparable to those of healthy volunteers, and produced a trend toward reduction in the level of IL-1Ra in BALF. The level of IL-1beta correlated significantly with the concentration of neutrophils in BALF (r=0.72, P<0.01), as well as with the level of IL-1Ra (r=0.688, P<0.05) and IL-8 (r=0.653, P<0.05). A nearly significant or significant correlation was observed between the concentration of neutrophils and levels of IL-1Ra or IL-8 in BALF (r=0.526, P=0.053 or r=0.776, P<0.01, respectively). There was also a significant relationship between FEV(1) and the concentration of neutrophils in BALF (r=0.524, P<0.05). Our results suggest that the relative amounts of IL-1beta and IL-1Ra or IL-8 may contribute, at least in part, to the neutrophil-mediated chronic airway inflammation in patients with chronic airway disease, and long-term erythromycin therapy may down-regulate the vigorous cycle between the cytokine network and neutrophil accumulation, with resultant reduction of neutrophil-mediated inflammatory response.
Kadota
J
J
Second Department of Internal Medicine, Nagasaki University School of Medicine, Japan.
Matsubara
Y
Y
Ishimatsu
Y
Y
Ashida
M
M
Abe
K
K
Shirai
R
R
Iida
K
K
Kawakami
K
K
Taniguchi
H
H
Fujii
T
T
Kaseda
M
M
Kawamoto
S
S
Kohno
S
S
D000328:Adult; D000368:Aged; D001988:Bronchiolitis / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology; D001992:Bronchoalveolar Lavage Fluid / Q000166:cytology*; D002000:Bronchospirometry; D016207:Cytokines / Q000378:metabolism; D004917:Erythromycin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007375:Interleukin-1 / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D009504:Neutrophils / Q000166:cytology / Q000187:drug effects / Q000502:physiology; D011659:Pulmonary Gas Exchange; D017472:Receptors, Interleukin-1 / Q000037:antagonists & inhibitors*; D012129:Respiratory Function Tests
D016207:Cytokines; D007375:Interleukin-1; D017472:Receptors, Interleukin-1; D004917:Erythromycin